acquisition - Padovalegal

GSK's Strategic $10.6 Billion Acquisition of Nuvalent Enhances Oncology Focus

In a significant move, GSK has announced its agreement to acquire Nuvalent for $10.6 billion, further solidifying its commitment to expanding its oncology portfolio.

Editorial Staff 4 days ago

World North America

GSK's $10.6 Billion Acquisition of Nuvalent Signals a Bold Step in Cancer Treatment

GSK's acquisition of Nuvalent for $10.6 billion represents a significant investment in the biopharma sector, particularly in targeted cancer therapies.

Editorial Staff 4 days ago

World Europe

Vandemoortele concedes Délifrance deal could hit UK competition, watchdog says

Concerns arise over potential competition impact from Vandemoortele's acquisition of Délifrance.

Editorial Staff 29 days ago

#acquisition

GSK's Strategic $10.6 Billion Acquisition of Nuvalent Enhances Oncology Focus

GSK's $10.6 Billion Acquisition of Nuvalent Signals a Bold Step in Cancer Treatment

Vandemoortele concedes Délifrance deal could hit UK competition, watchdog says